Predictors of Obstructive Sleep Apnoea in patients admitted for Acute Coronary Syndrome

Jordi de Batlle, Cecilia Turino, Alicia Sánchez-de-la-Torre, Jorge Abad, Joaquín Duran-Cantolla, R. Douglas McEvoy, Nick A. Antic, Olga Mediano, Valentín Cabriada, Maria José Masdeu, Joaquín Teran, Joan Valls, Ferran Barbé, Manuel Sánchez-de-la-Torre, on behalf of the Spanish Sleep Group.

ONLINE SUPPLEMENT

Table S1 online supplement. Additional baseline characteristics of the ISAACC patients according to Apnoea–hypopnoea index (AHI).

	AHI		p-value*
	< 15 (n=298)	≥ 15 (n=680)	
General characteristics			
Weight (kg)	76.9 ±14	83.6 ±15	<0.001
Height (m)	1.68 ±0.1	1.68 ±0.1	0.784
Neck circumference (cm)	40.0 ±4	41.2 ±4	<0.001
Waist circumference (cm)	99.3 ±12	104.6 ±12	<0.001
Hip circumference (cm)	101.4 ±9	105.7 ±11	<0.001
Waist to hip ratio	0.98 ±0.1	0.99 ±0.1	0.060
Smoking habit			0.957
never	81 (27%)	183 (27%)	
former	79 (27%)	175 (26%)	
current	138 (46%)	321 (47%)	
Total tobacco exposure (pack-years)	28 (15-40)	30 (15-42)	0.260
Alcohol habit			0.193
never	209 (72%)	476 (73%)	
former	7 (2%)	6 (1%)	
current	76 (26%)	174 (26%)	
Clinical characteristics and biological determinations			
Systolic blood pressure (mm Hg)	124 ±19	126 ±19	0.240
Diastolic blood pressure (mm Hg)	73 ±12	73 ±12	0.939
Heart rate (bpm)	71 ±13	72 ±14	0.252
NYHA class			0.111

I	159 (96%)	309 (90%)	
II	7 (4%)	27 (8%)	
III	0 (0%)	4 (1%)	
IV	0 (0%)	3 (1%)	
Catheterization	281 (97%)	651 (96%)	0.723
Obstruction	90 (80-100)	99 (90-100)	0.040
Diseased vessels n			0.440
1	145 (53%)	303 (48%)	
2	74 (27%)	187 (30%)	
≥3	55 (20%)	142 (22%)	
Stents implanted n	1.4 ±1	1.5 ±0.9	0.451
White cells(million/mm^3)	9.8 ±3.1	9.8 ±3.3	0.969
Red cells (million/mm^3)	4.7 ±0.6	4.6 ±0.7	0.421
Platelets (thousands/mm^3)	219 ±66	214 ±61	0.235
Prothrombin time (%)	82 ±33	83 ±32	0.699
Prothrombin time (s)	22 (11-30)	20 (11-30)	0.912
International normalized ratio	1.12 ±0.4	1.13 ±0.5	0.655
HDL cholesterol (mg/dL)	41.7 ±12	40.3 ±11	0.123
LDL cholesterol (mg/dL)	113 ±39	110 ±37	0.236
Aspartate transaminase (UI/L)	37 (25-72)	38 (23-70)	0.888
Alanine transaminase (UI/L)	30 (20-45)	29 (21-42)	0.761
Other pharmacological treatment			
Anticoagulants	14 (5%)	46 (7%)	0.230
Antacids	68 (23%)	177 (26%)	0.310
Antiplatelets	55 (19%)	157 (23%)	0.122
Bronchodilators	19 (7%)	25 (4%)	0.056

n (%), Mean ±SD or Median (P25-P75) as appropriate.

* Chi-square test, one-way ANOVA or Mann-Whitney test as appropriate.